The European Commission has granted marketing authorization for Multaq (dronedarone - 400mg Tablets) in all 27 European member states.

Multaq is indicated in adult clinically stable patients with a history of, or current non-permanent atrial fibrillation (AF) to prevent recurrence of AF or to lower ventricular rate.

Link:http://en.sanofi-aventis.com/binaries/20091130_multaq_approved_eu_en_tcm28-26788.pdf

Source:Sanofi-aventis